Comparative analysis of dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis

被引：0
|
作者：
Mueller, J. [1 ,2 ,3 ]
Schaedelin, S. [4 ]
Benkert, P. [4 ]
Haenni, P. [5 ]
Schmid, J. [5 ]
Derfuss, T. [1 ,2 ,3 ]
Kuhle, J. [1 ,2 ,3 ]
Yaldizli, O. [1 ,2 ,3 ]
机构：
[1] Univ Hosp Basel, MS Ctr, Neurol Clin & Policlin, Basel, Switzerland
[2] Univ Hosp Basel, Res Ctr Clin Neuroimmunol & Neurosci Basel RC2NB, Basel, Switzerland
[3] Univ Basel, Basel, Switzerland
[4] Univ Hosp Basel, Clin Trial Unit, Basel, Switzerland
[5] Swiss Federat Common Tasks Hlth Insurances SVK, Solothurn, Switzerland
来源：
MULTIPLE SCLEROSIS JOURNAL | 2021年 / 27卷 / 2_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P819
引用
收藏
页码：676 / 676
页数：1
相关论文
共 50 条
  • [31] Efficacy and safety of first line oral therapies in relapsing-remitting multiple sclerosis: Dimethyl fumarate vs teriflunomide in the Chieti experience
    Di Tommaso, V.
    Mancinelli, L.
    di Ioia, M.
    Farina, D.
    Travaglini, D.
    Pietrolongo, E.
    De Luca, G.
    Lugaresi, A.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 870 - 871
  • [32] COST-EFFECTIVENESS OF FINGOLIMOD, TERIFLUNOMIDE, DIMETHYL FUMARATE AND INTRAMUSCULAR INTERFERON BETA-1A IN RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Zhang, X.
    Hay, J. W.
    VALUE IN HEALTH, 2014, 17 (03) : A59 - A60
  • [33] Comparative effectiveness of teriflunomide and dimethyl fumarate in relapsing remitting multiple sclerosis. A Danish nationwide cohort study.
    Buron, M.
    Magyari, M.
    Chalmer, T. Ameri
    Hassanpour-Kalam-Roudy, H.
    Illes, Z.
    Mezei, Z.
    Roshanisefat, H.
    Rasmussen, P. V.
    Petersen, T.
    Tsakiri, A.
    Sellebjerg, F.
    Sorensen, P. Soelberg
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 85 - 86
  • [34] Teriflunomide for the treatment of relapsing-remitting multiple sclerosis: the Chieti experience
    di Ioia, M.
    Travaglini, D.
    Di Tommaso, V.
    Mancinelli, L.
    Pietrolongo, E.
    De Luca, G.
    Farina, D.
    Lugaresi, A.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 754 - 754
  • [35] Dimethyl Fumarate in the Treatment of Relapsing-Remitting Multiple Sclerosis: Patient Reported Outcomes and Perspectives
    Ozel, Osman
    Vaughn, Caila B.
    Eckert, Svetlana P.
    Jakimovski, Dejan
    Lizarraga, Alexis A.
    Weinstock-Guttman, Bianca
    PATIENT-RELATED OUTCOME MEASURES, 2019, 10 : 373 - 384
  • [36] Acute pancreatitis: possible association of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis
    Luo, Hongxiu
    Bhatt, Harsh
    Mohamad, Shaza
    Uhrik, Eric
    Sen, Shuvendu
    Mathew, Teena
    Yousif, Abdalla
    JOURNAL OF NEUROLOGY, 2015, 262 (03) : 779 - 780
  • [37] Risk factors for lymphopenia in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate
    Morales, Fabian Sierra
    Koralnik, Igor J.
    Gautam, Shiva
    Samaan, Soleil
    Sloane, Jacob A.
    JOURNAL OF NEUROLOGY, 2020, 267 (01) : 125 - 131
  • [38] Early versus delayed initiation of fingolimod or dimethyl fumarate in relapsing-remitting multiple sclerosis
    Lorscheider, J.
    Schadelin, S.
    Benkert, P.
    Lienert, C.
    Hanni, P.
    Derfuss, T.
    Decard, B.
    Kuhle, J.
    Kappos, L.
    Yaldizli, O.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 257 - 258
  • [39] A case of Legionnaires' disease in a patient on dimethyl fumarate therapy for relapsing-remitting multiple sclerosis
    Brandstadter, R.
    Sand, I. Katz
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 871 - 872
  • [40] Characterization of lymphopenia in relapsing-remitting multiple sclerosis patients treated with dimethyl fumarate and fingolimod
    Nakhaei-Nejad, M.
    Barilla, D.
    Lee, C-H.
    Blevins, G.
    Giuliani, F.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 618 - 618
12345